Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- “COI Management” to Be Specified in Unified Ethics Code for Epidemiological, Clinical Research
December 18, 2013
- Japan NIH to Be Staffed with 100-Plus Employees from 6 Govt Organizations
December 18, 2013
- MHLW Boots Up Project Team to Spur Clinical Application of Novel Drugs; Paper Due Out in April
December 17, 2013
- Japan Govt OKs Basic Policy for FY2014 Budget; Wording Tweaked in Favor of Healthcare Circles
December 17, 2013
- Diovan Panel to Reopen Discussions on Dec. 25, Hear from 3 Universities
December 17, 2013
- Amount of Funding from Pharma Companies to Healthcare Professionals Totals 466.6 Billion Yen in FY2012
December 17, 2013
- Bill Payers at Chuikyo Oppose Proposal on Evaluation of Generic Drug Use at DPC Hospitals; Subcommittee to Meet Again on Dec. 18
December 16, 2013
- First Generics of Livalo, Glivec Added to NHI Price List: MHLW
December 13, 2013
- No Diovan, Livalo AGs for December Generic NHI Listing
December 13, 2013
- PFSB Begins Discussions Toward Lifting Ban on Subcontracting of Safety Management Tasks
December 12, 2013
- MHLW Notifies Authorities of Expiration Date Extension for Relenza from 7 to 10 Years
December 12, 2013
- 3-Drug Therapy Including Simeprevir for Chronic Hepatitis C to Be Eligible for Medical Expense Assistance: MHLW
December 11, 2013
- September Price Settlement Rate at 73.5%; Low Figure Blamed on Pharmacy Chains
December 10, 2013
- Japan Diet Enacts Bill to Open Door for Online OTC Drug Sales
December 10, 2013
- FPMAJ OKs Concession Plan on Key Premium; Bill Payers Stick to Opposition
December 9, 2013
- Average Drug Price Discrepancy Rate at 8.2%: Health Ministry
December 9, 2013
- PMDA Aims to Solidify Partnerships with Overseas Regulators via February Symposium
December 9, 2013
- MHLW to Make Additional Appeal for Applicants for Special Grants to Produce Vaccines for New Strains of Influenza
December 6, 2013
- MHLW Calls for Caution on ADRs Associated with Axitinib, Bevacizumab
December 6, 2013
- Revision of Notification on Advanced Healthcare Introduces New Rules for Anticancer Drugs
December 5, 2013
ページ
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…